Enteric-coated mycophenolate sodium in de novo pediatric renal transplant patients

Pediatric Nephrology

Volumn 24, Issue 2, 2009, Pages 395-402

  Niaudet, Patrick ^a   Charbit, Marina ^a   Loirat, Chantal ^b   Lapeyraque, Anne Laure ^b   Tsimaratos, Michel ^c   Cailliez, Mathilde ^c   Foulard, Michel ^d   Dehennault, Maud ^d   Marquet, Pierre ^e   Chaouche Teyara, Kamel ^f   Lemay, Djamila ^f  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c TIMONE HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY OF LIMOGES   (France)

^f Laboratoires Novartis France   (France)

Author keywords

Cyclosporine A; EC MPS; MPA; Mycophenolic acid; Renal function; Renal transplantation

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN A; DACLIZUMAB; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID BETA D GLUCURONIDE; PHOSPHATE; PREDNISONE; STEROID; UNCLASSIFIED DRUG; VALACICLOVIR;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ADOLESCENT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BK VIRUS; CHILD; CHILDHOOD MORTALITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRAFT FAILURE; HAIR GROWTH; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; INTERSTITIAL LUNG DISEASE; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE NECROSIS; LEUKOPENIA; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; MULTICENTER STUDY; NEPHRECTOMY; NEUTROPENIA; OPEN STUDY; PHOSPHATE BLOOD LEVEL; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PYELONEPHRITIS; SEPSIS; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS INFECTION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CREATININE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PILOT PROJECTS; RECEPTORS, INTERLEUKIN-2; STEROIDS; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME;

EID: 58149090667     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-008-1031-7     Document Type: Article

References (29)

1. Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, Kaplan B (2003) Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 3:68-73
2. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C (1997) Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 63:39-47
3. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan B (2000) Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69:2405-2409
4. Staskewitz A, Kirste G, Tonshoff B, Weber LT, Böswald M, Burghard R, Helmchen U, Brandis M, Zimmerhackl LB (2001) Mycophenolate mofetil in pediatric renal transplantation without induction therapy: Results after 12 months of treatment. German Pediatric Renal Transplantation Study Group. Transplantation 71:638-644
5. Jungraithmayr T, Staskewitz A, Kirste G, Kirste G, Böswald M, Bulla M, Burghard R, Dippell J, Greiner C, Helmchen U, Klare B, Klaus G, Leichter HE, Mihatsch MJ, Michalk DV, Misselwitz J, Plank C, Querfeld U, Weber LT, Wiesel M, Tönshoff B, Zimmerhackl LB, German Pediatric Renal Transplantation Study Group (2003) Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years. Transplantation 75:454-461
6. Hocker B, Weber LT, Bunchman T, Rashford M, Tonshoff B, Tricontinental MMF Suspension Study Group (2005) Mycophenolate mofetil suspension in pediatric renal transplantation: Three-year data from the tricontinental trial. Pediatr Transplant 9:504-511
7. Cransberg K, Marlies Cornelissen EA, Davin JC, Van Hoeck KJ, Lilien MR, Stijnen T, Nauta J (2005) Improved outcome of pediatric kidney transplantation in the Netherlands - effect of the introduction of mycophenolate mofetil? Pediatr Transplant 9:104-111
8. Ferraris JR, Ghezzi LF, Vallejo G, Piantanida JJ, Araujo JL, Sojo ET (2005) Improved long-term allograft function in pediatric renal transplantation with mycophenolate mofetil. Pediatr Transplant 9:178-182
9. Otukesh H, Sharifian M, Basiri A, Simfroosh N, Hoseini R, Sedigh N, Golnari P, Rezai M, Fereshtenejad M (2005) Mycophenolate mofetil in pediatric renal transplantation. Transplant Proc 37:3012-3015
10. Arns W, Breuer S, Choudhury S, Taccard G, Lee J, Binder V, Roettele J, Schmouder R (2005) Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 19:199-206
11. Salvadori M, Holzer H, De Mattos A, Sollinger H, Arns W, Oppenheimer F, Maca J, Hall M, The ERL B301 Study Groups (2004) Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4:231-236
12. Budde K, Curtis J, Knoll G, Chan L, Neumayer HH, Seifu Y, Hall M, ERL B302 Study Group (2004) Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 4:237-243
13. Chan L, Mulgaonkar S, Walker R, Arns W, Ambühl P, Schiavelli R (2006) Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 81:1290-1297
14. Behrend M (2001) Adverse gastrointestinal effects of mycophenolate mofetil: Aetiology, incidence and management. Drug Saf 24:645-663
15. Ettenger R, Bartosh S, Choi L, Zhu W, Niederberger W, Campestrini J, Bastien MC, Schmouder R (2005) Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatr Transplant 9:780-787
16. Jacqz-Aigrain E, Shaghaghi E, Baudoin V, Popon M, Zhang D, Maisin A, Loirat C (2000) Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. Pediatr Nephrol 14:95-99
17. Garcia CD, Bittencourt VB, Tumelero A, Malheiros D, Antonello JS, Garcia VD (2006) Enteric-coated mycophenolate sodium (EC-MPS) in pediatric renal transplantation - single center experience. Transplantation 82[Suppl 3]:567
18. de Paula Meneses R, Kotsifas CH, Olandoski KP (2006) Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in children with stable renal transplant. Transplantation 82[Suppl 3]:510
19. World Medical Association (2000) World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. Available at: www.wma.net/e/policy/17-c_e.html
20. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y (1999) The Banff 97 working classification of renal allograft pathology. Kidney Int 55:713-723
21. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259-263
22. Weber LT, Lamersdorf T, Shipkova M, Niedmann PD, Wiesel M, Zimmerhackl LB, Staskewitz A, Schütz E, Mehls O, Oellerich M, Armstrong VW, Tönshoff B (1999) Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: A longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 21:498-506
23. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O, Zimmerhackl LB, Oellerich M, Tönshoff B (2002) The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: A report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol 13:759-768
24. Ghio L, Ferraresso M, Viganó SM, Ginevri F, Perfumo F, Gianoglio B, Murer L, Zacchello G, Dello Strologo L, Cardillo M, Tirelli S, Valente U, Edefonti A (2005) Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients. Transplant Proc 37:856-858
25. Oellerich M, Shipkova M, Schütz E, Wieland E, Weber L, Tönshoff B, Armstrong VW (2000) Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 22:20-26
26. Naesens M, de Loor H, Vanrenterghem Y, Kuypers DR (2007) The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation 84:362-373
27. Salvadori M, Holzer H, Civati G, Sollinger H, Lien B, Tomlanovich S, Bertoni E, Seifu Y, Marrast AC, ERL B301 Study Group on behalf of the ERL B301 Study Group (2006) Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients. Clin Nephrol 66:112-119
28. Budde K, Knoll G, Curtis J, Chan L, Pohanka E, Gentil M, Seifu Y, Marrast AC, Neumayer HH, ERL B302 Study Group (2006) Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS, myfortic). Clin Nephrol 66:103-111
29. Roberti I, Reisman L (1999) A comparative analysis of the use of mycophenolate mofetil in pediatric vs adult renal allograft recipients. Pediatr Transplant 3:231-235